| 抗PD-1/PD-L1抗体单药及联合治疗晚期胆道癌相关不良反应管理进展 |
| |
| 引用本文： | 马静,胡博,羊樟福,徐泱. 抗PD-1/PD-L1抗体单药及联合治疗晚期胆道癌相关不良反应管理进展[J]. 中国临床医学, 2022, 29(6): 1022-1029 |
| |
| 作者姓名： | 马静 胡博 羊樟福 徐泱 |
| |
| 作者单位： | 复旦大学附属中山医院,复旦大学附属中山医院,复旦大学附属中山医院,复旦大学附属中山医院 |
| |
| 基金项目： | 国家自然科学基金项目（面上项目,重点项目,重大项目） |
| |
| 摘 要： | 抗程序性死亡受体1(PD-1)及其配体（PD-L1）抗体已应用于临床多种肿瘤的治疗，在晚期胆道癌（biliary tract cancer,BTC）也取得显著疗效，但同时也有导致多种不良反应（adverse effects, AEs），如皮疹、腹泻及肝功能损伤等。本文对抗PD-1/PD-L1抗体单药及联药治疗BTC的疗效、相关AEs及管理对策作一综述。
|
| 关 键 词： | 胆道肿瘤 免疫检查点抑制剂 不良反应 管理 |
| 收稿时间： | 2022-05-23 |
| 修稿时间： | 2022-09-15 |
The adverse events management of anti-PD-1/PD-L1 antibody monotherapy and combination therapy in the treatment of advanced biliary tract cancer |
| |
| MA Jing,HU Bo,YANG Zhang-fu,XU Yang. The adverse events management of anti-PD-1/PD-L1 antibody monotherapy and combination therapy in the treatment of advanced biliary tract cancer[J]. Chinese Journal Of Clinical Medicine, 2022, 29(6): 1022-1029 |
| |
| Authors: | MA Jing HU Bo YANG Zhang-fu XU Yang |
| |
| Affiliation: | Fudan University, Zhongshan Hospital,Fudan University, Zhongshan Hospital,Fudan University, Zhongshan Hospital,Fudan University, Zhongshan Hospital |
| |
| Abstract: | Programmed death receptor 1 and its ligand (PD-1 / PD-L1) antibodies have been applied to the clinical treatment of a variety of tumors, including advanced biliary tract cancer (BTC), and have achieved significant efficacy, but there are also many adverse effects (AEs), This paper will briefly describe the efficacy of anti-PD-1/PD-L1 antibody monotherapy and combination therapy in BTC, focusing on adverse effects and their management strategies. |
| |
| Keywords: | biliary tract neoplasms immune checkpoint inhibitor adverse events |
|
| 点击此处可从《中国临床医学》浏览原始摘要信息 |
|
点击此处可从《中国临床医学》下载全文 |
|
